Active Transdermal Systems Enabling New Drug Therapies; New Survey by Greystone Associates Reveals Key Factors and Potential
Business Editors/Health/Medical Writers
AMHERST, N.H.–(BUSINESS WIRE)–March 22, 2004
Because of its ability to improve patient compliance, transdermal drug delivery continues to grow as an alternative to oral and invasive dosage forms, particularly for the treatment of chronic conditions. But future growth of transdermal patches will be restricted by the need to limit candidate drugs to molecules small enough to effectively pass through the stratum corneum, a limitation that excludes passive transdermal patches as a viable option for the growing number of protein and peptide therapeutic compounds that will represent an increasing share of future drug therapies.
To expand the limits of transdermal drug delivery, developers are employing energy sources such as ultrasound, heat and electrical current to affect active transport through the skin. Another approach is the modification or removal of surface skin layers, a group of technologies collectively referred to as microporation, which can be used alone or in conjunction with energy-enabled active transport to expand the size and type of drug molecules capable of transdermal delivery. These techniques can increase the upper molecular size limit dramatically, opening up a host of opportunities for transdermal delivery.
“Large molecule therapeutics for chronic conditions such as rheumatoid arthritis, hormone deficiency, and chronic pain will be a major growth engine for the medical sector,” explains George Perros, Greystone Managing Director. “Evolving active transdermal systems will be well-positioned to address a significant segment of the large molecule biological drugs expected to emerge from the convergence of biotechnology, automated drug discovery and genome mapping.”
More information is available at www.greystoneassociates.org .
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
COPYRIGHT 2004 Business Wire
COPYRIGHT 2004 Gale Group